Celgene Corporation s in-depth stock price analysis indicates that the stock price has dropped -5.21% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 6.27% . Looking at the past 52 week period, the stock price is up at 12.85% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Celgene Corporation has a positive value of 15.65 compared to overall market. Celgene Corporation (NASDAQ:CELG) has tumbled 0.03% during the past week and has dropped 1.59% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.83%. Celgene Corporation (NASDAQ:CELG) has underperformed the index by 3.35% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Celgene Corporation (NASDAQ:CELG) stock ended Friday session in the red zone in a volatile trading. The stock closed down 1.13 points or 0.97% at $115.61 with 3,102,837 shares getting traded. Post opening the session at $116.7, the shares hit an intraday low of $115.2501 and an intraday high of $117 and the price was in this range throughout the day. The company has a market cap of $89,621 million and the number of outstanding shares has been calculated to be 775,203,500 shares. The 52-week high of Celgene Corporation (NASDAQ:CELG) is $127 and the 52-week low is $94.39.
Celgene Corporation Last issued its quarterly earnings results on Jan 26, 2017. The company reported $1.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $1.60. The company had revenue of $2980.50 million for the quarter, compared to analysts expectations of $3021.34 million. The companys revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.18 EPS.
Company has reported several Insider transactions to the SEC, on Nov 30, 2016, Rupert Vessey (officer ) sold 2,500 shares at 123.18 per share price.On Nov 15, 2016, Michael F. Pehl (officer ) sold 22,052 shares at 121.09 per share price.On Nov 14, 2016, Robert J Hugin (director officer ) sold 100,000 shares at 120.00 per share price.
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.